Catharina Lange

Catharina Lange

Auto-generated profile, based on publicly available information

Catharina Lange

Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in NeuroImage
Verified
Journal Article
Closed access
GGGabriel Gonzalez-Escamilla
Gabriel Gonzalez-Escamilla
CLCatharina Lange
Catharina Lange
STStefan Teipel
Stefan Teipel
RBRalph Buchert
Ralph Buchert
MGMichel J. Grothe
Michel J. Grothe

1 May 2019 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
MWMiranka Wirth
Miranka Wirth
CSClaudia Schwarz
Claudia Schwarz
GBGloria Benson
Gloria Benson
NHNora Horn
Nora Horn
RBRalph Buchert
Ralph Buchert
AFAgnes Flöel
Agnes Flöel
Background: Given the global increase in the aging population and age-related diseases, the promotion of healthy aging is one of the most crucial public health issues. This trial aims to contribute to the establishment of effective approaches to promote cognitive and brain health in older individuals with subjective cognitive decline (SCD). Presence of SCD is known to increase the risk of objective cognitive decline and progression to dementia due to Alzheimer’s disease. Therefore, it is our primary goal to determine whether spermidine supplementation has a positive impact on memory performance in this at-risk group, as compared with placebo. The secondary goal is to examine the effects of spermidine intake on other neuropsychological, behavioral, and physiological parameters.Methods: The SmartAge trial is a monocentric, randomized, double-blind, placebo-controlled phase IIb trial. The study will investigate 12 months of intervention with spermidine-based nutritional supplementation (target intervention) compared with 12 months of placebo intake (control intervention). We plan to recruit 100 cognitively normal older individuals with SCD from memory clinics, neurologists and general practitioners in private practice, and the general population. Participants will be allocated to one of the two study arms using blockwise randomization stratified by age and sex with a 1:1 allocation ratio. The primary outcome is the change in memory performance between baseline and post-intervention visits (12 months after baseline). Secondary outcomes include the change in memory performance from baseline to follow-up assessment (18 months after baseline), as well as changes in neurocognitive, behavioral, and physiological parameters (including blood and neuroimaging biomarkers), assessed at baseline and post-intervention.Discussion: The SmartAge trial aims to provide evidence of the impact of spermidine supplementation on memory performance in older individuals with SCD. In addition, we will identify possible neurophysiological mechanisms of action underlying the anticipated cognitive benefits. Overall, this trial will contribute to the establishment of nutrition intervention in the prevention of Alzheimer’s disease.Trial registration: ClinicalTrials.gov,NCT03094546. Registered 29 March 2017—retrospectively registered.Protocol version: Based on EA1/250/16 version 1.5

18 January 2021 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
MGMalo Gaubert
Malo Gaubert
CLCatharina Lange
Catharina Lange
AGAntoine Garnier-Crussard
Antoine Garnier-Crussard
TKTheresa Köbe
Theresa Köbe
SBSalma Bougacha
Salma Bougacha
MWMiranka Wirth
Miranka Wirth
Background: White matter hyperintensities (WMH) are frequently found in Alzheimer’s disease (AD). Commonly considered as a marker of cerebrovascular disease, regional WMH may be related to pathological hallmarks of AD, including beta-amyloid (Aβ) plaques and neurodegeneration. The aim of this study was to examine the regional distribution of WMH associated with Aβ burden, glucose hypometabolism, and gray matter volume reduction. Methods: In a total of 155 participants (IMAP+ cohort) across the cognitive continuum from normal cognition to AD dementia, FLAIR MRI, AV45-PET, FDG-PET, and T1 MRI were acquired. WMH were automatically segmented from FLAIR images. Mean levels of neocortical Aβ deposition (AV45-PET), temporo-parietal glucose metabolism (FDG-PET), and medial-temporal gray matter volume (GMV) were extracted from processed images using established AD meta-signature templates. Associations between AD brain biomarkers and WMH, as assessed in region-of-interest and voxel-wise, were examined, adjusting for age, sex, education, and systolic blood pressure. Results: There were no significant associations between global Aβ burden and region-specific WMH. Voxel-wise WMH in the splenium of the corpus callosum correlated with greater Aβ deposition at a more liberal threshold. Region- and voxel-based WMH in the posterior corpus callosum, along with parietal, occipital, and frontal areas, were associated with lower temporo-parietal glucose metabolism. Similarly, lower medial-temporal GMV correlated with WMH in the posterior corpus callosum in addition to parietal, occipital, and fontal areas. Conclusions: This study demonstrates that local white matter damage is correlated with multimodal brain biomarkers of AD. Our results highlight modality-specific topographic patterns of WMH, which converged in the posterior white matter. Overall, these cross-sectional findings corroborate associations of regional WMH with AD-typical Aß deposition and neurodegeneration.

27 October 2018 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
GBGloria Benson
Gloria Benson
AHAndrea Hildebrandt
Andrea Hildebrandt
CLCatharina Lange
Catharina Lange
CSClaudia Schwarz
Claudia Schwarz
TKTheresa Köbe
Theresa Köbe
MWMiranka Wirth
Miranka Wirth
Cerebrovascular pathology, quantified by white matter lesions (WML), is known to affect cognition in aging, and is associated with an increased risk of dementia. The present study aimed to investigate whether higher functional connectivity in cognitive control networks mitigates the detrimental effect of WML on cognition. Nondemented older participants (≥ 50 years; n = 230) underwent cognitive evaluation, fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI), and resting state functional magnetic resonance imaging (fMRI). Total WML volumes were quantified algorithmically. Functional connectivity was assessed in preselected higher-order resting state networks, namely the fronto-parietal, the salience, and the default mode network, using global and local measures. Latent moderated structural equations modeling examined direct and interactive relationships between WML volumes, functional connectivity, and cognition. Larger WML volumes were associated with worse cognition, having a greater impact on executive functions (β = −0.37, p < 0.01) than on memory (β = −0.22, p < 0.01). Higher global functional connectivity in the fronto-parietal network and higher local connectivity between the salience network and medial frontal cortex significantly mitigated the impact of WML on executive functions, (unstandardized coefficients: b = 2.39, p = 0.01; b = 3.92, p = 0.01) but not on memory (b = -5.01, p = 0.51, b = 2.01, p = 0.07, respectively). No such effects were detected for the default mode network. Higher functional connectivity in fronto-parietal and salience networks may protect against detrimental effects of WML on executive functions, the cognitive domain that was predominantly affected by cerebrovascular pathology. These results highlight the crucial role of cognitive control networks as a neural substrate of cognitive reserve in older individuals.

31 August 2019 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MWMarkus Wenzel
Markus Wenzel
FMFausto Milletari
Fausto Milletari
JKJulia Krüger
Julia Krüger
CLCatharina Lange
Catharina Lange
MSMichael Schenk
Michael Schenk
RBRalph Buchert
Ralph Buchert

9 November 2015 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
CLCatharina Lange
Catharina Lange
PSPer Suppa
Per Suppa
LFLars Frings
Lars Frings
WBWinfried Brenner
Winfried Brenner
LSLothar Spies
Lothar Spies
RBRalph Buchert
Ralph Buchert
Background: Positron emission tomography (PET) with the glucose analog F-18-fluorodeoxyglucose (FDG) is widely used in the diagnosis of neurodegenerative diseases. Guidelines recommend voxel-based statistical testing to support visual evaluation of the PET images. However, the performance of voxel-based testing strongly depends on each single preprocessing step involved. Objective: To optimize the processing pipeline of voxel-based testing for the prognosis of dementia in subjects with amnestic mild cognitive impairment (MCI). Methods: The study included 108 ADNI MCI subjects grouped as ‘stable MCI’ ( n = 77) or ‘MCI-to-AD converter’ according to their diagnostic trajectory over 3 years. Thirty-two ADNI normals served as controls. Voxel-based testing was performed with the statistical parametric mapping software (SPM8) starting with default settings. The following modifications were added step-by-step: (i) motion correction, (ii) custom-made FDG template, (iii) different reference regions for intensity scaling, and (iv) smoothing was varied between 8 and 18 mm. The t-sum score for hypometabolism within a predefined AD mask was compared between the different settings using receiver operating characteristic (ROC) analysis with respect to differentiation between ‘stable MCI’ and ‘MCI-to-AD converter’. The area (AUC) under the ROC curve was used as performance measure. Results: The default setting provided an AUC of 0.728. The modifications of the processing pipeline improved the AUC up to 0.832 ( p = 0.046). Improvement of the AUC was confirmed in an independent validation sample of 241 ADNI MCI subjects ( p = 0.048). Conclusion: The prognostic value of voxel-based single subject analysis of brain FDG PET in MCI subjects can be improved considerably by optimizing the processing pipeline.